Retatrutide and trizepatide constitute a new class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor agonists exhibit promising therapeutic efficacy in the treatment of type 2 diabetes. Retatrutide, a once-weekly subcutaneous injection, acti